PTGS2 and neoplasm: Together, these results suggest that the triple combination of COX-2 inhibition with cytotoxic therapy and immunotherapy can improve outcomes by limiting tumor relapse and metastasis in an adjuvant setting of TNBC, where improvements in therapeutic outcome are urgently required.